CIS Pharma is a privately held biopharmaceutical company based in the Basel Area, Switzerland. We develop next-gen immuno-conjugates, ADCs and radioligand treatments for cancer patients with poor prognosis and prone to high spread of metastases. Our assets include two targeting moieties against CD 171 and CD 276, and a polymer carrier technology to overcome the current limitations of immuno-conjugates. The technology offers high-yield labeling of proteins, increases DAR and creates precision combination therapies.